Payment overview · 2025
General Payments
$1,415.54
67 reported records · 18 companies
Healthcare provider profile · identity verified
Mohitkumar Ardeshana, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · REDLANDS, CA · NPI 1467867135
Verified facts
What the public records show
CMS Open Payments records show Mohitkumar Ardeshana, M.D. received $1,415.54 in general payments during 2025 across 67 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $291.18 | 20.6% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $186.32 | 13.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.89 | 11.4% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.19 | 10.3% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.60 | 10.1% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.07 | 6.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $90.17 | 6.4% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.54 | 3.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.85 | 2.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.56 | 2.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.14 | 2.3% | 2 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $30.49 | 2.1% | 1 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $27.44 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.78 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.99 | 1.3% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.29 | 1.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.80 | 1.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.24 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,415.54 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $291.18 | 14 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $129.01 | 10 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $105.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.26 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $72.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.74 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.67 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.67 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.61 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.85 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| XCELL Normalized: xcell |
Device | Bioventus LLC | $30.49 | 1 | 2025 |
Source payment records
|
|||||
| ESOPHYX Normalized: esophyx |
Device | Merit Medical Systems Inc | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 119 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
119 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 484 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 118 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 361 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 64 |
| Losartan Potassium | Losartan Potassium | 300 | 65 |
| Lisinopril | Lisinopril | 288 | 66 |
| Gabapentin | Gabapentin | 267 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 46 |
| Metformin Hcl | Metformin Hcl | 205 | 51 |
| Simvastatin | Simvastatin | 204 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 71 |
| Omeprazole | Omeprazole | 179 | 52 |
| Furosemide | Furosemide | 176 | 56 |
| Ozempic | Semaglutide | 166 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 46 |
| Jardiance | Empagliflozin | 154 | 33 |
| Potassium Chloride | Potassium Chloride | 143 | 31 |
| Trazodone Hcl | Trazodone Hcl | 140 | 45 |
| Donepezil Hcl | Donepezil Hcl | 136 | 28 |
| Glipizide | Glipizide | 132 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | suppressed |
| Linzess | Linaclotide | 119 | 22 |
| Carvedilol | Carvedilol | 116 | 31 |
| Lorazepam | Lorazepam | 116 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 37 |
| Eliquis | Apixaban | 113 | 25 |
| Ibuprofen | Ibuprofen | 111 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 55 |
| Azithromycin | Azithromycin | 102 | 81 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 23 |
| Alprazolam | Alprazolam | 99 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 65 |
| Benazepril Hcl | Benazepril Hcl | 80 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 20 |
| Ondansetron Odt | Ondansetron | 74 | 29 |
| Mounjaro | Tirzepatide | 72 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 12 |
| Vascepa | Icosapent Ethyl | 71 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 27 |
| Finasteride | Finasteride | 69 | 20 |
| Tramadol Hcl | Tramadol Hcl | 69 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 42 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 25 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 17 |
| Methylprednisolone | Methylprednisolone | 44 | 38 |
| Prednisone | Prednisone | 44 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 12 |
| Lactulose | Lactulose | 43 | 13 |
| Metformin Er Gastric | Metformin Hcl | 43 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 42 | suppressed |
| Vraylar | Cariprazine Hcl | 41 | 11 |
| Allopurinol | Allopurinol | 40 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Naproxen | Naproxen | 39 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 38 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Gemfibrozil | Gemfibrozil | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Pimozide | Pimozide | 31 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Famotidine | Famotidine | 25 | 13 |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 17 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 16 |
| Irbesartan | Irbesartan | 20 | 12 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 12 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Estradiol | Estradiol | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Flovent Hfa | Fluticasone Propionate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,415.54 · 67 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, AMYVID, CAPLYTA, COMIRNATY, CREON, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ESOPHYX, EVENITY, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TEPEZZA, The Cologuard Plus Collection Kit, VOWST, VRAYLAR, Wegovy, XCELL, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error